급성허혈뇌졸중 환자의 초기 혈중 요산농도와 발병3개월 후 기능예후와의 연관성
Association between Baseline Serum Uric Acid Levels with Functional Outcomes at 3 Months after Acute Ischemic Stroke
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Currently available data suggests that uric acid (UA) functions as an antioxidant after acute ischemic stroke(AIS). Nevertheless, the prognostic value of serum UA in AIS is controversial. The aim of this study was to determine therelationship between UA and functional outcomes after AIS. Methods: UA levels were analyzed within 48 hours of stroke onset in patients between 2007 and 2012. Mean serum UAlevels were compared between patients with good and poor functional outcomes (modified Rankin Scale [mRS] score,0-2 versus 3-6, respectively) at 3 months poststroke, and with and without early neurological improvement (ENI, ≥4-versus <4-point differences on the National Institutes of Health Stroke Scale [NIHSS] score after 7 days). Results: Serum UA levels differed according to the sex, age, stroke subtype, and presence of diabetes mellitus, smoking,and atrial fibrillation. Multivariate logistic regression analysis revealed an association between good functional outcomeat 3 months and male gender, young age, history of dyslipidemia, good functional status before stroke (mRS score, 0-2),and low stroke severity (i.e., NIHSS score) on admission. However, higher serum UA levels were no longer associatedwith a good functional outcomes (odds ratio, 1.387; 95% confidence interval, 0.857-2.244; p=0.521). The mean serum UAlevels did not differ significantly between patients with and without ENI. Conclusions: There was no association between serum UA levels and functional outcomes at 3 months in AIS.
Abstract
Background: Currently available data suggests that uric acid (UA) functions as an antioxidant after acute ischemic stroke(AIS). Nevertheless, the prognostic value of serum UA in AIS is controversial. The aim of this study was to determine therelationship between UA and functional outcomes after AIS. Methods: UA levels were analyzed within 48 hours of stroke onset in patients between 2007 and 2012. Mean serum UAlevels were compared between patients with good and poor functional outcomes (modified Rankin Scale [mRS] score,0-2 versus 3-6, respectively) at 3 months poststroke, and with and without early neurological improvement (ENI, ≥4-versus <4-point differences on the National Institutes of Health Stroke Scale [NIHSS] score after 7 days). Results: Serum UA levels differed according to the sex, age, stroke subtype, and presence of diabetes mellitus, smoking,and atrial fibrillation. Multivariate logistic regression analysis revealed an association between good functional outcomeat 3 months and male gender, young age, history of dyslipidemia, good functional status before stroke (mRS score, 0-2),and low stroke severity (i.e., NIHSS score) on admission. However, higher serum UA levels were no longer associatedwith a good functional outcomes (odds ratio, 1.387; 95% confidence interval, 0.857-2.244; p=0.521). The mean serum UAlevels did not differ significantly between patients with and without ENI. Conclusions: There was no association between serum UA levels and functional outcomes at 3 months in AIS.
참고문헌 (39)
- Dawson J, "Baseline serum urate and 90-day functional outcomes following acute ischemic stroke", Cerebrovasc Dis, 28, pp.202~203 (2009)
- Kanellis J, "Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2", Hypertension, 41, pp.1287~1293 (2003)
- Miedema I, "Lack of association between serum uric acid levels and out-come in acute ischemic stroke", J Neurol Sci, 319, pp.51~55 (2012)
- Brand FN, "Hyperuricemia as a risk factor of coronary heart disease: The Framingham Study", Am J Epidemiol, 121, pp.11~18 (1985)
- Iribarren C, "Correlates of uric acid and its association with asymptomatic carotid atherosclerosis: the ARIC Study. Atherosclerosis Risk in Communities", Ann Epidemiol, 6, pp.331~340 (1996)
- De Scheerder IK, "Myocardial malondialdehyde and uric acid release after short-lasting coronary occlusions during coronary angioplasty: po-tential mechanisms for free radical generation", Am J Cardiol, 68, pp.392~395 (1991)
- Lehto S, "Serum uric acid is a strong predictor of stroke in patients with non-insulin-dependent dia-betes mellitus", Stroke, 29, pp.635~639 (1998)
- Puig JG, "Uric acid as a cardiovascular risk factor in arte-rial hypertension", J Hypertens, 17, pp.869~872 (1999)
- Li M, "Hyperuricemia and risk of stroke: a systematic review and meta-analysis of prospective studies", Atherosclerosis, 232, pp.265~270 (2014)
- Crouse JR, "Risk factors for extracranial carotid artery atherosclerosis", Stroke, 18, pp.990~996 (1987)
- Wannamethee SG, "Serum urate and the risk of major coronary heart disease events", Heart, 78, pp.147~153 (1997)
- Romanos E, "Uric acid reduces brain damage and improves the benefits of rt-PA in a rat model of thromboembolic stroke", J Cereb Blood Flow Metab, 27, pp.14~20 (2007)
- Amaro S, "A pilot study of dual treatment with recombinant tissue plasminogen activa-tor and uric acid in acute ischemic stroke", Stroke, 38, pp.2173~2175 (2007)
- Bickel C, "Serum uric acid as an independent predictor of mortality in patients with angiographically proven coronary artery disease", Am J Cardiol, 89, pp.12~17 (2002)
- Madsen TE, "Serum uric acid independently predicts mortality in patients with significant, angiographically defined coronary disease", Am J Nephrol, 25, pp.45~49 (2005)
- Becker BF, "Towards the physiological function of uric acid", Free Radic Biol Med, 14, pp.615~631 (1993)
- Zhang B, "Is elevated SUA associated with a worse outcome in young Chinese patients with acute cerebral ischemic stroke?", BMC Neurol, 10, pp.82~ (2010)
- Hong JM, "Influence of recanalization on uric acid patterns in acute ischemic stroke", Cerebrovasc Dis, 29, pp.431~439 (2010)
- Nieto FJ, "Uric acid and serum antioxidant capacity: a reaction to atherosclerosis?", Atherosclerosis, 148, pp.131~139 (2000)
- Chamorro A, "Prognostic significance of uric acid serum concentration in patients with acute ischemic stroke", Stroke, 33, pp.1048~1052 (2002)
- Chiquete E, "Serum uric acid and out-come after acute ischemic stroke: PREMIER study", Cerebrovasc Dis, 35, pp.168~174 (2013)
- 유경호, "한국 뇌졸중 자료은행에 등록된 10,811명의 급성기 허혈성 뇌졸중 환자 분석: 병원기반 다의료기관 전향적 자료등록 연구", 대한신경과학회지, 24(6), pp.535~543 (2006), 대한신경과학회
- Adams HP Jr, "Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in acute stroke treatment", Stroke, 24, pp.35~41 (1993)
- Muir KW, "Comparison of neurological scales and scoring systems for acute stroke prognosis", Stroke, 27, pp.1817~1820 (1996)
- Brott T, "Measurements of acute cerebral infarction: a clinical examination scale", Stroke, 20, pp.864~870 (1989)
- van Swieten JC, "Interobserver agreement for the assessment of handicap in stroke patients", Stroke, 19, pp.604~607 (1988)
- Weir CJ, "Serum urate as an in-dependent predictor of poor outcome and future vascular events after acute stroke", Stroke, 34, pp.1951~1956 (2003)
- Becker LB, "New concepts in reactive oxygen species and cardiovascular reperfusion physiology", Cardiovasc Res, 61, pp.461~470 (2004)
- Poss WB, "Regulation of xanthine dehydrogenase and xanthine oxidase activity by hypoxia", Am J Physiol, 270, pp.L941~L946 (1996)
- Higgins P, "Xanthine oxidase inhibition for the treatment of stroke disease: a novel therapeutic approach", Expert Rev Cardiovasc Ther, 9, pp.399~401 (2011)
- Brouns R, "Decrease in uric acid in acute ischemic stroke corre-lates with stroke severity, evolution and outcome", Clin Chem Lab Med, 48, pp.383~390 (2010)
- Polidori MC, "Increased plasma levels of lipid hydroperoxides in patients with is-chemic stroke", Free Radic Biol Med, 25, pp.561~567 (1998)
- Fagan SC, "Targets for vascular protection after acute ischemic stroke", Stroke, 35, pp.2220~2225 (2004)
- 김준현, "중등도 이상 허혈성 뇌졸중 환자의 뇌졸중 아형에 따른 요산과 조기 예후와의 관계", 대한신경과학회지, 28(3), pp.149~156 (2010), 대한신경과학회
- Mahomed FA, "On chronic Bright's disease, and its essential symptoms", Lancet, 113, pp.399~401 (1879)
- Culleton BF, "Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study", Ann Intern Med, 131, pp.7~13 (1999)
- Dawson J, "Uric acid and xanthine oxidase: future ther-apeutic targets in the prevention of cardiovascular disease?", Br J Clin Pharmacol, 62, pp.633~644 (2006)
- Dawson J, "Uric acid reduction: a new paradigm in the management of cardiovascular risk?", Curr Med Chem, 14, pp.1879~1886 (2007)
- Abuja PM, "Ascorbate prevents prooxidant effects of urate in oxidation of human low density lipoprotein", FEBS Lett, 446, pp.305~308 (1999)